Showing results (551-560 of 2,362) with videos related to

Sort By:
Pageof 237
BMC Infectious Diseases|March 3, 2006
Diarrhea, CD4 counts and enteric infections in a hospital - based cohort of HIV-infected patients around Varanasi, IndiaSuresh V S Attili, A K Gulati, V P Singh, et al.
Biochemical and Biophysical Research Communications|February 13, 2001
Relationship between NF-kappaB and trypsinogen activation in rat pancreas after supramaximal caerulein stimulationA J Hietaranta, A K Saluja, L Bhagat, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 26, 2000
Short-course of oral miltefosine for treatment of visceral leishmaniasisS Sundar, A Makharia, D K More, et al.
Tropical Medicine & International Health : TM & IH|June 1, 2011
Monitoring drug effectiveness in kala-azar in Bihar, India: cost and feasibility of periodic random surveys vs. a health service-based reporting systemP Malaviya, R P Singh, S P Singh, et al.
The Journal of the Association of Physicians of India|January 26, 2007
Study on clinico-epidemiological profile of HIV patients in eastern IndiaJ Chakravarty, H Mehta, A Parekh, et al.
The British Journal of Ophthalmology|May 19, 2006
Incidence of ocular complications in patients with multibacillary leprosy after completion of a 2 year course of multidrug therapyE Daniel, T J Ffytche, J H Kempen, et al.
Tropical Medicine & International Health : TM & IH|May 22, 2010
Risk factors for visceral leishmaniasis in India: further evidence on the role of domestic animalsS P Singh, E Hasker, A Picado, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|November 15, 2006
Epidermal growth factor receptor status predicts local response to radical radiotherapy in muscle-invasive bladder cancerA J Colquhoun, S Sundar, P H Rajjayabun, et al.
The New England Journal of Medicine|December 10, 1999
Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasisT K Jha, S Sundar, C P Thakur, et al.
Gynecologic Oncology|August 7, 2004
Phase II trial of Oxaliplatin and 5-Fluorouracil/Leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapyS Sundar, R P Symonds, M P Decatris, et al.
Pageof 237